30th Mar 2023 16:03
MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Non-Executive Chair Richard Douglas buys 80,000 shares at average USD4.32, worth USD345,480, on Wednesday. Now has 100,000 shares, a 0.1% stake.
Current stock price: 367.05 pence, up 7.2% in London on Thursday
12-month change: down 34%
By Tom Waite, Alliance News editor
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
MaxCyte